Clinical trials: Induction Phase
Phase 2, Radiotherapy-Induced Immune Priming
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.
- Conditions
- Phase 2, Radiotherapy-Induced Immune Priming, Elranatamab, Relapsed Refractory Multiple Myeloma (RRMM)
- Trial name
- NCT07382739
- Testing
- Elranatamab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
End-Stage Renal Disease, Kidney Failure
Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection
T regulatory cells (T regs) are responsible for immune tolerance in solid organ transplant patients. This study will evaluate the treatment of children with kidney transplants either with Campath and other immune system…
- Trial name
- NCT01446484
- Testing
- CD4+CD25+CD127lowFoxP3+ T regulatory cells injection, Alemtuzumab, Mycophenolate mofetil
- Where
- 2 sites in Russia
- Volunteers
- 30 people
- Sponsor
- Pirogov Russian National Research Medical University
Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor
CREATE: Cross-tumoral Phase 2 With Crizotinib
The study will primarily assess the antitumor activity of crizotinib in a variety of tumors with alterations in ALK and/or MET pathways.
- Conditions
- Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor, Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1, Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma
- Trial name
- CREATE (NCT01524926)
- Testing
- Crizotinib (PF-02341066)
- Where
- 25 sites in Belgium, France and 8 more
- Volunteers
- 582 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Neoplasms
A Clinical Trial to Reduce Skin Burn Induced by Breast Radiotherapy Using Intensity Modulated Radiation Therapy (IMRT)
The purpose of this study is to determine whether the use of a 3D missing tissue compensation radiation technique during a standard adjuvant breast radiotherapy delivering a dose of 50Gy in 25 treatments could reduce…
- Trial name
- NCT00187343
- Testing
- Breast IMRT
- Where
- 2 sites in Canada
- Volunteers
- 340 people
- Sponsor
- Sunnybrook Health Sciences Centre
The Immune Dysregulation Polyendocrinopathy Enteropathy X-linked Syndrome is a Primary Immunodeficiency Caused by Pathogenic Variants in Forkhead Box Protein 3
Study Evaluating a Gene Therapy for IPEX Syndrome Through the Expression of FOXP3 on Deficient T Cells to Produce Tregs-like.
The purpose of this study is to evaluate the safety and efficacy of FOXP3-T4 (an autologous gene therapy) alone or in combination with low-dose IL-2 for the treatment of IPEX syndrome.
- Trial name
- THERIPEX (NCT07697118)
- Testing
- FOXP3-T4 drug product, ILT-101
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sarcoma
Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.
Monocentric, phase I study for advanced sarcoma with adoptive immunotherapy with Cytokine-Induced Killer (CIK). In the first part of the study Patient's' peripheral blood will be collected and CIK cell expansion and storage will…
- Trial name
- NCT04802070
- Testing
- Autologous CIK
- Where
- Italy
- Volunteers
- 7 people
- Sponsor
- Prof. Franca Fagioli
AML, Childhood, Acute Myeloid Leukemia
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
The goal of this clinical trial is to estimate the rate (probability) of complete remission or complete remission with incomplete count recovery (CR/CRi) with negative MRD after induction I and II, event-free survival (EFS), and…
- Trial name
- GMCAII (NCT06221683)
- Testing
- Homoharringtonine, Cytarabine, Etoposide
- Where
- 13 sites in China
- Volunteers
- 500 people
- Sponsor
- Children's Hospital of Soochow University
Head and Neck Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004094
- Testing
- carboplatin, fluorouracil, hydroxyurea
- Where
- 4 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Bronchopulmonary Dysplasia, BPD
Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial
This is a follow-up study to investigate the long-term safety and efficacy of PNEUMOSTEM® versus placebo, for the treatment of BPD in premature infants.
- Trial name
- NCT04003857
- Testing
- PNEUMOSTEM®, normal saline
- Where
- 2 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Medipost Co Ltd.
MBL-Deficient, Neutropenia
Study on Mannan Binding Lectin (MBL) Substitution in MBL-Deficient Children With Chemotherapy-Induced Neutropenia
The pharmacokinetics, and clinical and biological effects of MBL replacement therapy in MBL-deficient children during chemotherapy-induced neutropenia were studied.
- Trial name
- NCT00138736
- Testing
- Mannan Binding Lectin (MBL), Mannan Binding Lectin
- Where
- 2 sites in Netherlands
- Volunteers
- 12 people
- Sponsor
- Prothya Biosolutions
Chemotherapy-induced Nausea and Vomiting
Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)
The purpose of this study was to determine the appropriate dosing regimen of fosaprepitant, when administered with ondansetron (with or without dexamethasone), for the prevention of CINV in children from birth to <17 years of…
- Trial name
- NCT01697579
- Testing
- Fosaprepitant, Ondansetron, 5-hydroxytryptamine 3 antagonist
- Volunteers
- 240 people
- Sponsor
- Merck Sharp & Dohme LLC
Oral Complications, Quality of Life
Pilocarpine in Treating Patients With Dry Mouth Caused by Opioids
RATIONALE: Pilocarpine may help to relieve dry mouth in patients receiving opioids for cancer therapy. It is not yet known whether pilocarpine is more effective than no further treatment for this condition.
- Trial name
- NCT00003686
- Testing
- pilocarpine hydrochloride
- Where
- 2 sites in Canada
- Volunteers
- 4 people
- Sponsor
- NCIC Clinical Trials Group
Pregnancy-Associated Hypertension, Gestational Hypertension
Community Health Worker Support to Lower Blood Pressure After a Pregnancy With High Blood Pressure
High blood pressure during or after pregnancy (such as preeclampsia, gestational hypertension, eclampsia, or Hemolysis, Elevated Liver enzymes, and Low Platelet (HELLP) syndrome) raises a mother's risk of heart disease later in…
- Conditions
- Pregnancy-Associated Hypertension, Gestational Hypertension, Preeclampsia, Eclampsia
- Trial name
- AW2H (NCT07778966)
- Testing
- Alabama Womb to Heart Solution (AW2H) Community Health Worker (CHW) Program, Usual postpartum care with self-measured blood pressure education and home blood pressure monitor
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- University of Alabama at Birmingham
Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia
This phase II trial is studying the side effects and how well decitabine works when given as maintenance therapy after standard therapy in treating patients with previously untreated acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
- Trial name
- NCT00416598
- Testing
- Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Busulfan
- Where
- 46 sites in United States
- Volunteers
- 546 people
- Sponsor
- National Cancer Institute (NCI)
Lupus Nephritis
Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Phase Treatment in Lupus Nephritis
This is a pilot study to evaluate the efficacy and safety of Tacrolimus Sustained-release Capsules (ADVAGRAF) for the induction therapy of Lupus Nephritis (LN) (V, III +V, IV+V).
- Trial name
- NCT01288664
- Testing
- ADVAGRAF
- Where
- China
- Sponsor
- Sun Yat-sen University
Chemotherapy Induced Nausea and Vomiting
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)
This study will compare the safety and efficacy of a three-day oral aprepitant regimen (aprepitant plus ondansetron) to ondansetron alone in the prevention of chemotherapy-induced nausea and vomiting (CINV) in the 120 hours…
- Trial name
- NCT01362530
- Testing
- Aprepitant 125 mg, Aprepitant 80 mg, Aprepitant powder for suspension (PFS)
- Volunteers
- 307 people
- Sponsor
- Merck Sharp & Dohme LLC
Leukemia, Lymphocytic, Acute, Adult
Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study
This is a prospective, multicenter, observational study aimed at exploring the efficacy and safety of reduced-dose chemotherapy followed by frontline therapy with blinatumomab in patients aged 15-65 with newly diagnosed…
- Trial name
- NCT06649422
- Testing
- Blinatumomab
- Volunteers
- 36 people
- Sponsor
- Shandong University
Acute Myeloid Leukemia
Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
This phase I trial studies the side effects and the best dose of selinexor when give together with standard chemotherapy, high dose cytarabine and mitoxantrone hydrochloride, in treating patients with acute myeloid leukemia.
- Trial name
- NCT02573363
- Testing
- Cytarabine, Mitoxantrone Hydrochloride, Selinexor
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Chicago
Latrodectism
Black Widow Spider Antivenin for Patients With Systemic Latrodectism
The purpose of this study is to test the efficacy and safety of a new antivenom called Analatro® for treating black widow spider bites in patients who present to a hospital emergency room within 24 hours of symptom onset.
- Trial name
- BWSP3 (NCT00657540)
- Testing
- Analatro, Saline
- Where
- 16 sites in United States
- Volunteers
- 60 people
- Sponsor
- Instituto Bioclon S.A. de C.V.
RETT Syndrome With Proven MECP2 Mutation, Rett Syndrome
Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome
The FENRTT2 study will investigate the efficacy and safety of a medicinal cannabis plant extract with extremely low THC (delta-9-tetrahydrocannabinol), NTI164, on Rett syndrome (RTT) in a crossover design.
- Trial name
- TRANSCEND (NCT07257978)
- Testing
- NTI164
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Fenix Innovation Group